Egis has previously marketed locally applied dermatological products, and with this acquisition, the company seeks to expand this portfolio further. 
 
"The production of the flagship medicine in this newly acquired product line will be brought back to Hungary. Following a successful technology transfer, it will be manufactured at Egis's recently inaugurated, state-of-the-art galenical plant in Körmend," added Csaba Poroszlai, CEO of Egis, in the announcement. 
 
Egis Pharmaceuticals is a pharmaceutical company with more than 110 years of history, headquartered in Hungary, and equipped with facilities for active ingredient and drug manufacturing. Its activities cover all value-creating processes of the pharmaceutical industry, from research and development to the production of active ingredients and finished products, as well as sales. 
 
Teva Pharmaceutical Industries Ltd. has decided to divest this product line as part of its global business strategy and will focus on other global, locally applied dermatological brands in the future. 
 
The transition of marketing and promotion for the product line will take place on December 17, 2024. As part of the transaction, both parties have worked to ensure continuous product availability for consumers.